• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does NSAID Use Impact Risk for Ovarian Cancer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Case-control studies have demonstrated an association between low-dose aspirin and decreased risk for ovarian cancer  
    • Increased risk (19% higher) has been identified with use of nonaspirin NSAIDs  
  • Barnard et al. (JAMA Oncology, 2018) assessed whether long term use of regular aspirin or nonaspirin NSAIDs reduce risk ovarian cancer

METHODS: 

  • Prospective Cohort study  
  • NSAID use and ovarian cancer diagnosis data from 2 prospective cohorts 
    • Nurses’ Health Study (NHS)  
    • Nurses’ Health Study II (NHSII) 
  • Data collected for each analgesic type (aspirin, low-dose aspirin, nonaspirin NSAIDs, and acetaminophen) 
    • Timing, duration, frequency, and number of tablets used 
    • Exposure information (updated every 2 to 4 years) 
  • Primary outcome: Hazard ratios (HRs) for association between analgesic type with risk of epithelial ovarian cancer

RESULTS: 

  • NHS study  
    • 93,664 women  
    • Mean age at baseline: 45.9 years 
    • 93% of participants were non-Hispanic white 
  • NHSII study  
    • 111,834 women  
    • Mean age at baseline: 34.2 years 
    • 92% were non-Hispanic white 
  • Total 205,498 women | 1054 cases of incident epithelial ovarian cancer 
  • Significant associations between aspirin and ovarian cancer risk were not observed when current vs nonuse of any aspirin was evaluated regardless of dose  
    • Hazard ratio (HR) 0.99; 95% CI, 0.83-1.19 
  • Low-dose (≤100-mg) aspirin was associated with an inverse relationship for ovarian cancer  
    • HR 0.77; 95% CI, 0.61-0.96 
    • No association for standard-dose aspirin was observed 
  • Current use of nonaspirin NSAIDs was positively associated with ovarian cancer risk compared with nonuse  
    • HR 1.19; 95% CI, 1.00-1.41 
  • In addition, the following was associated with increased risk  
    • Duration of use ≥10 years (P = .02 for trend)  
    • Cumulative average tablets per week of ≥10 vs <1 (P = .03 for trend)  
    • 2,500 or more tablet-days (P = .006 for trend)

CONCLUSION: 

  • Low-dose aspirin was associated with decreased risk for ovarian cancer 
  • Recommendations advising adults aged 50 to 59 years with a 10-year risk of cardiovascular disease greater than 10% to initiate low-dose aspirin therapy is unlikely to increase the risk of ovarian cancer  
  • Nonaspirin NSAIDs were not associated with reduced risk for ovarian cancer and heavier use and duration may be associated with an increased risk for ovarian cancer

Learn More – Primary Sources: 

Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses’ Health Studies

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does Low-Dose Aspirin Reduce Risk of First Cardiovascular Events in Individuals at Moderate Risk?
Low Dose Aspirin and Breast Cancer Prevention – Results from the CTS Cohort
Does Diclofenac Introduce a Disproportionate risk for Cardiovascular Disease?
ACC/AHA Blood Pressure Guideline: New Classification System and Treatment Targets

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site